Abacavir adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Abacavir}} {{CMG}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect" |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Abacavir}} | {{Abacavir}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Adverse Reaction== | |||
:The following adverse reactions are discussed in greater detail in other sections of the labeling: | |||
:• Serious and sometimes fatal hypersensitivity reaction. In one trial, once-daily dosing of abacavir was associated with more severe hypersensitivity reactions [see Boxed Warning, Warnings and Precautions (5.1)]. | |||
:• Lactic acidosis and severe hepatomegaly [see Boxed Warning, Warnings and Precautions (5.2)]. | |||
:• Immune reconstitution syndrome [see Warnings and Precautions (5.3)]. | |||
:• Fat redistribution [see Warnings and Precautions (5.4)]. | |||
:• Myocardial infarction [see Warnings and Precautions (5.5)]..<ref name="Dellinger-2013">{{Cite journal | last1 = Dellinger | first1 = RP. | last2 = Levy | first2 = MM. | last3 = Rhodes | first3 = A. | last4 = Annane | first4 = D. | last5 = Gerlach | first5 = H.| last6 = Opal | first6 = SM. | last7 = Sevransky | first7 = JE. | last8 = Sprung | first8 = CL. | last9 = Douglas | first9 = IS. | title = Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. | journal = Intensive Care Med | volume = 39 | issue = 2 | pages = 165-228 | month = Feb | year = 2013 | doi = 10.1007/s00134-012-2769-8 | PMID = 23361625 }}</ref> | |||
==References== | ==References== | ||
Revision as of 21:56, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reaction
- The following adverse reactions are discussed in greater detail in other sections of the labeling:
- • Serious and sometimes fatal hypersensitivity reaction. In one trial, once-daily dosing of abacavir was associated with more severe hypersensitivity reactions [see Boxed Warning, Warnings and Precautions (5.1)].
- • Lactic acidosis and severe hepatomegaly [see Boxed Warning, Warnings and Precautions (5.2)].
- • Immune reconstitution syndrome [see Warnings and Precautions (5.3)].
- • Fat redistribution [see Warnings and Precautions (5.4)].
- • Myocardial infarction [see Warnings and Precautions (5.5)]..[1]
References
- ↑ Dellinger, RP.; Levy, MM.; Rhodes, A.; Annane, D.; Gerlach, H.; Opal, SM.; Sevransky, JE.; Sprung, CL.; Douglas, IS. (2013). "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012". Intensive Care Med. 39 (2): 165–228. doi:10.1007/s00134-012-2769-8. PMID 23361625. Unknown parameter
|month=ignored (help)
Adapted from the FDA Package Insert.